Jiawei Qifuyin Enhances Immunity and Improves Cognitive Impairment in APP/PS1 Mice Through Modulation of Neuroinflammatory Pathways
Jiahua Cheng,Wujuan Li,Lanlin Wang,Yu Gao,Yueran Ma,Min Zhou,Tian Yang,Changwu Yue,Long Yan,Yuhong Lyu
DOI: https://doi.org/10.2147/jir.s479899
IF: 4.5
2024-11-27
Journal of Inflammation Research
Abstract:Jiahua Cheng, 1, &ast Wujuan Li, 1, &ast Lanlin Wang, 1, &ast Yu Gao, 1 Yueran Ma, 1 Min Zhou, 1 Tian Yang, 1 Changwu Yue, 1, 2 Long Yan, 3 Yuhong Lyu 1, 2 1 Yan'an Key Laboratory of Microbial Drug Innovation and Transformation, School of Basic Medicine, Yan'an University, Yan'an, Shaanxi, People's Republic of China; 2 Shaanxi Engineering and Technological Research Center for Conversation and Utilization of Regional Biological Resources, Yan'an University, Yan'an, Shaanxi, People's Republic of China; 3 Medical Imaging Center, Yan'an Traditional Chinese Medicine Hospital, Yan'an, Shaanxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Long Yan; Yuhong Lyu, Email ; Purpose: To explore the protective effects and mechanisms of Jiawei Qifuyin on APP/PS1 mice, a model for Alzheimer's disease (AD). Methods: Network pharmacology tools were used to predict anti-AD targets and signaling pathways affected by Jiawei Qifuyin. In vitro studies assessed antioxidant and oxygen radical scavenging abilities, immune cell proliferation, and inflammatory cytokine levels in lipopolysaccharide-induced BV2 microglial cells. Cognitive ability in APP/PS1 mice was evaluated using the Morris Water Maze test. mRNA expression of neuroinflammatory factors, changes in intestinal microbiota, and short-chain fatty acid content were analyzed post-treatment. Results: Network pharmacology predicted that Jiawei Qifuyin affects AKT1, TNF-α, and AGE/RAGE pathways. It showed concentration-dependent antioxidant effects and modulated immune cell proliferation. IL-2, IL-6, and TNF-α levels in LPS-induced BV2 cells were significantly reduced. Treated animals exhibited improved cognitive performance, decreased brain amyloid-beta levels, and downregulated expression of IL-1β, IL-6, RAGE, and NF-κB. Significant changes in intestinal microbiota composition and SCFA content were observed. Conclusion: Jiawei Qifuyin may enhance immunity and improve cognitive impairment in APP/PS1 mice through regulation of inflammatory factors, gut microbiota, and the gut-brain axis. Keywords: Alzheimer's disease, Jiawei Qifuyin, neuroinflammation, intestinal microbiota, short chain fatty acid Alzheimer's disease (AD) is a central neurodegenerative disease, in which cognitive function gradually deteriorates with age. The pathological features mainly manifest in brain β-amyloid protein deposition, neuronal fiber entanglement, and central nervous system inflammation. 1,2 AD is a multifactor complex disorder, and currently, most treatments for AD are based on the cholinergic hypothesis, β-amyloid deposition hypothesis, tau protein hypothesis, and lysosomal acidification disorder hypothesis. With the gradual progress in research on AD, increasing evidence shows that the onset of AD is related to multiple factors, including family genetics, Aβ plaque-related neurodegeneration, neurofibrillary degeneration, synaptic dysfunction and neurotransmitter imbalance, neuroinflammation, infectious disease hypothesis, intestinal microbiota imbalance, gene mutations, oxidative stress, and autophagic lysosomal acidification. However, owing to the uncertainty and complexity of the pathogenesis of AD, the current progress in the treatment of AD is still very difficult. 3 Neuroinflammation is a defense response that occurs when brain tissues and cells are stimulated by disease-causing agents. Neuroinflammation is closely associated with microglia and astrocytes. 4 Stimulation of the brain with disease-causing factors causes the activation of these cells, which in turn produces inflammatory factors that damage the brain. However, the incidence of AD is still significantly increasing, causing a heavy burden on patients, their families, and society. Therefore, it is important and urgent to develop drugs that can reduce the incidence of AD and intervene in the development process of AD based on the pathological mechanisms of AD. The drugs used to treat AD clinically include donepezil, litramine, galantamine, memantine hydrochloride, and the new drug aducanumab, which were approved by the FDA in 2021. Although these drugs have achieved certain results in the treatment of AD, they do not fundamentally solve the problem of irreversible disease progression. Furthermore, many drugs have failed in clinical trials, forcing people to recognize the need to change the traditional development strategies for treating AD. The presence of amyloid proteins is insufficient to cause dementia. It is precisely because of the interaction between amyloid p -Abstract Truncated-
immunology